On May 14, 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, reported that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on May 21, 2025 (Press release, Renovorx, MAY 14, 2025, View Source [SID1234653103]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Bagai will share recent business developments, highlighting continuing momentum with the Company’s RenovoCath commercialization, as well as progress in the ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG) for treatment in locally advanced pancreatic cancer (LAPC), which is currently under investigation, and has not yet been approved for commercial sale.
Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 12:40 p.m. ET
Speaker: Shaun Bagai, CEO
Moderator: Scott Henry, AGP Managing Director and Healthcare Analyst
Webcast: View Source
To schedule a one-on-one investor meeting with Mr. Bagai, please contact your A.G.P. representative or KCSA Strategic Communications at [email protected].
About RenovoCath
Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of LAPC. RenovoRx’s first investigational drug-device combination product candidate using the TAMP therapy platform is enabled with the Company’s FDA-cleared RenovoCath device for the intra-arterial administration of chemotherapy (intra-arterial gemcitabine, known as IAG).